Navigation Links
Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
Date:11/25/2008

PRINCETON, N.J., Nov. 25 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference in New York and the 2008 Mid-Atlantic Capital Conference in Philadelphia. Mr. Jackson will provide a corporate overview and an update on the company's clinical development programs. The presentations will be held as follows:

    Piper Jaffray Health Care Conference
    Tuesday, December 2, 2008 at 3:50pm ET at the New York Palace Hotel

    Mid-Atlantic Capital Conference
    Wednesday, December 3, 2008 at 2:44pm ET in the Life Science Room of the Pennsylvania Convention Center

About Celator

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
4. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
5. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that its three Promissory ... Portage, who advanced $ 100,000 each in July 2014 ... their Notes and related Coupons converted into 3,500,001 restricted ... carried 5% coupon. Both the Note and the coupon ...
(Date:9/29/2014)... , Sept. 29, 2014 Research ... "Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph Market ... & Region - Global Trends & Forecast to 2013 ... A process analyzer is a process analytical instrument ... real-time. It has redefined the way by which companies ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, is pleased to ... Chairman of the Board of Directors of SQI, replacing ... serve as a Director on the Board and will ... "We are very pleased to have Mr. Winkley ...
Breaking Biology Technology:Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 2
... /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies,in the ... that the Company,received approval from the PRC ... commence clinical trial of its new Human ...
... Cytotoxic ... Compound Market, ... development organization supporting the,pharmaceutical industry -- today announced the opening ... The 18,000 sq. ft. facility includes newly constructed analytical and,formulation ...
... (Nasdaq: SGMO ) announced today that Edward Lanphier,Sangamo,s ... progress of,Sangamo,s ZFP Therapeutic development programs and an overview ... Tuesday, September 23,2008, at the 2008 UBS Global Life ... will be webcast live and may be accessed via ...
Cached Biology Technology:China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3Pharmatek Announces Official Opening of New Highly-Potent & Cytotoxic Development and Manufacturing Facility 2Sangamo BioSciences to Present at the UBS Global Life Sciences Conference 2
(Date:9/29/2014)... . Montreal, ... expectant mother was deprived of electricity during Quebec,s Ice ... a new study finds., Scientists from the Douglas Mental ... distinctive ,signature, in the DNA of children born in ... months after the event, researchers recruited women who had ...
(Date:9/29/2014)... Sclerosis (MS) were able to safely tolerate treatment with ... study published today in the journal Multiple Sclerosis ... first of its kind, was conducted by researchers at ... and collaborators at several other institutions. , While ... in the data also suggested that a preparation of ...
(Date:9/27/2014)... The first direct comparison of treating non-squamous lung ... to cisplatin has shown that the two combinations ... with more frequent adverse events. , At the ... from Chonnam National University Medical School, South Korea, ... trial that included 149 patients with non-squamous non-small ...
Breaking Biology News(10 mins):Cells from placentas safe for patients with multiple sclerosis 2Docetaxel or pemetrexed with cisplatin achieve comparable outcomes in non-squamous Lu Ca 2
... molecule made by the human body that triggers the immune ... to new research published today in Nature Medicine . ... that if scientists could block this signal, it may be ... is the most common autoimmune disease, affecting around 1 in ...
... canopies bear little resemblance to their seedlings, many described ... "Seedlings of Barro Colorado Island and the Neotropics," published ... Garwood, professor of plant biology at the University of ... describing seedling stages of tropical plants 25 years ago ...
... Lieberman (I-CT) and John Cornyn (R-TX) today introduced the ... ensure free, timely, online access to the published results ... proposed bill is welcomed by the Alliance for Taxpayer ... others formed to support open public access to publicly ...
Cached Biology News:New trigger for chronic inflammation in rheumatoid arthritis discovered 2New guide to tropical seedlings: Essential to climate change research 2Taxpayer Alliance applauds bill to broaden access to federal research results 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
...
... Gel loading buffer is especially formulated for ... nucleic acids. The gel loading solution contains ... to add density and facilitate sample loading. ... that require divalent cations and SDS has ...
Biology Products: